Thomas A Hope1,2,3, Ali Afshar-Oromieh4,5, Matthias Eiber6, Louise Emmett7,8,9, Wolfgang P Fendler10, Courtney Lawhn-Heath1, Steven P Rowe11. 1. 1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave, San Francisco, CA 94143-0628. 2. 2 Department of Radiology, San Francisco VA Medical Center, San Francisco, CA. 3. 3 UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. 4. 4 Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland. 5. 5 Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany. 6. 6 Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Germany. 7. 7 Department of Diagnostic Imaging, St. Vincent's Public Hospital, Sydney, Australia. 8. 8 The Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Sydney, Australia. 9. 9 University of New South Wales, Sydney, Australia. 10. 10 Klinik für Nuklearmedizin, Universitätsklinikum, Essen, Germany. 11. 11 The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
OBJECTIVE: The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION: PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.
OBJECTIVE: The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION:PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.
Authors: Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning Journal: N Engl J Med Date: 2017-01-12 Impact factor: 91.245
Authors: A P Kozikowski; F Nan; P Conti; J Zhang; E Ramadan; T Bzdega; B Wroblewska; J H Neale; S Pshenichkin; J T Wroblewski Journal: J Med Chem Date: 2001-02-01 Impact factor: 7.446
Authors: Matthias Eiber; Tobias Maurer; Michael Souvatzoglou; Ambros J Beer; Alexander Ruffani; Bernhard Haller; Frank-Philipp Graner; Hubert Kübler; Uwe Haberkorn; Michael Eisenhut; Hans-Jürgen Wester; Jürgen E Gschwend; Markus Schwaiger Journal: J Nucl Med Date: 2015-03-19 Impact factor: 10.057
Authors: Thomas A Hope; Charles Truillet; Eric C Ehman; Ali Afshar-Oromieh; Rahul Aggarwal; Charles J Ryan; Peter R Carroll; Eric J Small; Michael J Evans Journal: J Nucl Med Date: 2016-09-22 Impact factor: 10.057
Authors: Roberto A Salas Fragomeni; Tali Amir; Sara Sheikhbahaei; Susan C Harvey; Mehrbod S Javadi; Lilja B Solnes; Ana P Kiess; Mohamad E Allaf; Martin G Pomper; Michael A Gorin; Steven P Rowe Journal: J Nucl Med Date: 2018-03-15 Impact factor: 10.057
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Frederik L Giesel; B Hadaschik; J Cardinale; J Radtke; M Vinsensia; W Lehnert; C Kesch; Y Tolstov; S Singer; N Grabe; S Duensing; M Schäfer; O C Neels; W Mier; U Haberkorn; K Kopka; C Kratochwil Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-26 Impact factor: 9.236
Authors: Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Stefano Fanti; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Ken Herrmann; Constantin Lapa; Steven P Rowe Journal: J Nucl Med Date: 2019-02-22 Impact factor: 10.057
Authors: Jean V Joseph; Ralph Brasacchio; Chunkit Fung; Jay Reeder; Kevin Bylund; Deepak Sahasrabudhe; Shu Yuan Yeh; Ahmed Ghazi; Patrick Fultz; Deborah Rubens; Guan Wu; Eric Singer; Edward Schwarz; Supriya Mohile; James Mohler; Dan Theodorescu; Yi Fen Lee; Paul Okunieff; David McConkey; Hani Rashid; Chawnshang Chang; Yves Fradet; Khurshid Guru; Janet Kukreja; Gerald Sufrin; Yair Lotan; Howard Bailey; Katia Noyes; Seymour Schwartz; Kathy Rideout; Gennady Bratslavsky; Steven C Campbell; Ithaar Derweesh; Per-Anders Abrahamsson; Mark Soloway; Leonard Gomella; Dragan Golijanin; Robert Svatek; Thomas Frye; Seth Lerner; Ganesh Palapattu; George Wilding; Michael Droller; Donald Trump Journal: Bladder Cancer Date: 2018-10-03
Authors: Ali Afshar-Oromieh; Bernd Vollnberg; Ian Alberts; Alexandrine Bähler; Christos Sachpekidis; Lotte Dijkstra; Fabian Haupt; Silvan Boxler; Tobias Gross; Tim Holland-Letz; George Thalmann; Johannes Heverhagen; Axel Rominger; Kirsi Härmä; Martin H Maurer Journal: Eur J Nucl Med Mol Imaging Date: 2019-07-27 Impact factor: 9.236
Authors: Sonia Gaur; Esther Mena; Stephanie A Harmon; Maria L Lindenberg; Stephen Adler; Anita T Ton; Joanna H Shih; Sherif Mehralivand; Maria J Merino; Bradford J Wood; Peter A Pinto; Ronnie C Mease; Martin G Pomper; Peter L Choyke; Baris Turkbey Journal: AJR Am J Roentgenol Date: 2020-07-08 Impact factor: 3.959
Authors: Verena I Böhmer; Wiktor Szymanski; Keimpe-Oeds van den Berg; Chantal Mulder; Piermichele Kobauri; Hugo Helbert; Dion van der Born; Friederike Reeβing; Anja Huizing; Marten Klopstra; Douwe F Samplonius; Ines F Antunes; Jürgen W A Sijbesma; Gert Luurtsema; Wijnand Helfrich; Ton J Visser; Ben L Feringa; Philip H Elsinga Journal: Chemistry Date: 2020-07-21 Impact factor: 5.236
Authors: Christian W Wichmann; Uwe Ackermann; Stan Poniger; Kenneth Young; Benjamin Nguyen; Gordon Chan; John Sachinidis; Andrew M Scott Journal: J Labelled Comp Radiopharm Date: 2020-11-02 Impact factor: 1.921